EDSA • NASDAQ
Edesa Biotech, Inc.
$1.51
Stock Details
| Market Cap | 12,605,722 |
|---|---|
| Day Change | 0.611 (67.96%) |
| Volume | 95,409,311 |
| Avg Volume | 162,901 |
| Price Range | 0.72-2.95 |
Overview
| Country | CA |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
Company Profile
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Financial Overview
| 52 Week High | 2.9516 |
|---|---|
| 52 Week High Date | 2025-10-22 |
| 52 Week Low | 0.72 |
| 52 Week Low Date | 2026-02-20 |
| 10D Avg Trading Vol | 0.70529 |
| YTD Price Return Daily | -36.6901 |
| MTD Price Return Daily | -23.1624 |
Cash Flow
| TTM/Share | -3.44776 |
|---|---|
| Annual/Share | -1.0253 |
| Quarterly/Share | -1.0253 |
Price-to-Earnings
| Annual Ratio | 10.6745 |
|---|---|
| Quarterly Ratio | 10.6745 |
| TTM |
Earnings Per Share
| Annual | -1.9297 |
|---|---|
| 3Y Growth | |
| 5Y Growth | |
| Quarterly YOY Growth |
Price-to-Book
| Ratio | 0.6027 |
|---|---|
| Annual Ratio | 1.396 |
| TTM | 1.396 |